Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity?

Oncologist

Volumn 16, Issue 12, 2011, Pages 1667-1668

  Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CARBOPLATIN; CISPLATIN; MAGNESIUM; OXALIPLATIN;

ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY; COLORECTAL CANCER; DISTAL PARESTHESIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MUSCLE CRAMP; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SENSORY NEUROPATHY; SKIN TINGLING; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CALCIUM; CHELATION THERAPY; HUMANS; MAGNESIUM; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 84855175795     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0343     Document Type: Article

References (16)

1. Kim BJ, Park HR, Roh HJ et al. Chemotherapyrelated polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 2010;19:1097-1103.
2. Brundage M, Osoba D, Bezjak A et al. Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:5078-5081.
3. Cavaletti G, Alberti P, Frigeni B et al. Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011;13:180-190.
4. Windebank AJ, Grisold W. Chemotherapyinduced neuropathy. J Peripher Nerv Syst 2008;13: 27-46.
5. Argyriou AA, Bruna J, Marmiroli P et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 2011 Sep 9 [Epub ahead of print].
6. Khattak MA. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity? The Oncologist 2011;16:1780-1783.
7. Wolf S, Barton D, Kottschade L et al. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 2008;44: 1507-1515.
8. Argyriou AA, Polychronopoulos P, Iconomou G et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008;34:368-377.
9. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol 2011;12: 1151-1161.
10. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 2010;6:657-666.
11. Cavaletti G, Frigeni B, Lanzani F et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 2010;46:479-494.
12. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9:739-744.
13. Hughes R. NCI-CTC vs TNS: Which tool is better for grading the severity of chemotherapyinduced peripheral neuropathy? Nat Clin Pract Neurol 2008;4:68-69.
14. Leonard GD, Wright MA, Quinn MG et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005;5:116.
15. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
16. CI-PERINOMS Study Group. CI-PERINOMS: chemotherapy-induced peripheral neuropathy outcome measures study. J Peripher Nerv Syst 2009;14:69-71.